NCT05196087 Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!)
| NCT ID | NCT05196087 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Health Network, Toronto |
| Condition | Breast Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2022-07-20 |
| Primary Completion | 2027-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2022-07-20 with a primary completion date of 2027-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Patients who have undergone curative treatment may be at risk of relapse. This study will collect, annotate, and sequence biospecimens (blood, stool, and tissue) from patients across different tumor types to detect molecular residual disease (MRD) before metastases become radiographically or clinically detectable. This will allow for early cancer interception, and hopefully prolong relapse-free survival across tumor types.
Eligibility Criteria
Inclusion Criteria: 1. Patients with histological confirmation of a solid tumor. 2. Patients must have early stage or locally advanced disease that is planned for or have undergone curative treatment. 3. Patient must be ≥ 18 years old. 4. All patients must have signed and dated an informed consent form. Exclusion Criteria: None
Contact & Investigator
Lillian Siu, MD
PRINCIPAL INVESTIGATOR
Princess Margaret Hospital, Canada
Frequently Asked Questions
Who can join the NCT05196087 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05196087 currently recruiting?
Yes, NCT05196087 is actively recruiting participants. Contact the research team at celeste.yu@uhn.ca for enrollment information.
Where is the NCT05196087 trial being conducted?
This trial is being conducted at Toronto, Canada.
Who is sponsoring the NCT05196087 clinical trial?
NCT05196087 is sponsored by University Health Network, Toronto. The principal investigator is Lillian Siu, MD at Princess Margaret Hospital, Canada. The trial plans to enroll 500 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.